Multiple myeloma in dogs: treatment, prognosis and clinical trials
Dogs · USA & Canada
Understanding multiple myeloma
Multiple myeloma is a cancer of plasma cells, the antibody-producing cells of the immune system. It is usually a systemic disease rather than one isolated mass and can affect bone marrow, bones, kidneys, calcium levels and blood proteins. The complications it is causing are often as important as the cancer itself when treatment starts.
What does the prognosis look like?
Many dogs respond to treatment. A classic treatment study found a typical survival time of about 18 months, with much better outcomes in dogs that responded. Kidney injury, high calcium, severe anemia, abnormal blood proteins and bone damage can make the outlook more serious. The early treatment response is therefore more useful than treating 18 months as a deadline.
What matters next
Look first for problems the abnormal plasma cells or proteins are causing now: anemia, kidney injury, high calcium, bone pain or fractures, bleeding or neurologic signs from thickened blood. Treating those complications can be as important initially as choosing the anti-cancer drug.
Where are you now?
Kidney injury, high calcium, or anemia is present
These complications can be as important as the tumor burden itself. Supportive care and systemic treatment may need to start promptly rather than waiting only for a specialist visit.
There is painful bone disease
Radiation can be useful for selected painful focal lesions while systemic treatment addresses disease throughout the body. Pain control and fracture or spinal risk should be explicit parts of the plan.
Treatment has already started
Follow the monoclonal protein or other disease marker together with blood counts, kidney values, calcium, and clinical signs. Response helps determine whether a treatment change is actually needed.
If you are waiting for oncology
Do not focus only on the cancer label. Kidney injury, hypercalcemia, anemia, hyperviscosity and painful bone lesions can require treatment promptly while the full myeloma workup is being completed.
Questions to ask your oncologist
- Which myeloma complications are present right now?
- What marker will we follow to know whether treatment is working?
- Are there focal bone lesions that need radiation or another local intervention?
How the diagnosis may appear in the record
Diagnosis usually rests on several findings rather than one test: abnormal plasma cells, a monoclonal protein, bone lesions, and organ effects may contribute. Keep serum or urine protein studies, marrow or tissue results, imaging, calcium, kidney values, CBC, and the marker chosen to follow response.
Changes to watch for at home
Watch for weakness, pale gums, bleeding, increased thirst or urination, vomiting, confusion, vision changes, bone pain, lameness, or sudden inability to walk. Collapse, fracture, severe neurologic change, uncontrolled bleeding, or profound weakness needs urgent care.
How it is usually treated
Systemic drug treatment is the main therapy because myeloma affects the body rather than one isolated site. Alkylating chemotherapy with a corticosteroid is a common starting approach, with other drugs used when needed. Radiation can help painful focal bone lesions, while supportive care treats kidney injury, high calcium, anemia or hyperviscosity.
What can affect treatment choices
Kidney injury, high calcium, anemia, abnormal blood proteins, bone lesions and treatment response matter more than the diagnosis name alone because these complications often determine urgency.
Tests that may matter
CBC and chemistry, calcium, serum and urine protein studies, imaging for bone lesions and bone-marrow evaluation may all contribute. The important goal is to confirm that this is systemic plasma-cell disease and identify kidney, bone, blood or protein-related complications that need treatment.